IBSA USA Revenue and Competitors

IBSA USA is the subsidiary of IBSA Group, the largest privately owned pharmaceutical company in Switzerland. IBSA is committed to improving patient quality of life through research, innovation, and the development of effective drugs and cutting-edge technologies.\n\nIBSA USA markets two unique levothyroxine formulations in the U.S. for the treatment of hypothyroidism: Tirosint® (levothyroxine sodium) capsules and Tirosint®-SOL (levothyroxine sodium) oral solution. IBSA also markets Licart™ (diclofenac epolamine) topical system 1.3%, the only once-a-day topical nonsteroidal anti-inflammatory (NSAID) available in the U.S. to treat acute pain due to minor strains, sprains, and contusions.\n\nIBSA is focused on the health and well-being of patients and driven by the desire to bring therapeutic alternatives to as many people as possible. IBSA Group bases its philosophy on four sustainable pillars: Person, Innovation, Quality, and Responsibility.\n\nFor more information about Tirosint, Tirosint-SOL, or Licart, including Full Prescribing Information, go to each brand’s respective website.